An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients
In a 6-week open-label study, ten newly admitted depressed patients were treated with tomoxetine, a selective inhibitor of noradrenaline reuptake. After 7 days of drug washout, patients were given an initial dose of 40 mg/day which was gradually increased to a maximum of 70 mg/day (median 50 mg/day). There was a statistically (P<0.001) and clinically significant improvement in the mean symptomatology of the patients measured on the Hamilton Depression Rating Scale. The drug had an early onset of action, a specific effect on mood and no sedative properties.
Key wordsTomoxetine LY139603 Antidepressant Affective disorder Depression
Unable to display preview. Download preview PDF.
- Bartko JJ, Carpenter WT (1976) On the methods and theory of reliability. J Nerv Ment Dis 163:307–317Google Scholar
- Diagnostic and Statistical Manual of Mental Disorders (3rd ed) (1980) American Psychiatric Association, Washington, DCGoogle Scholar
- Lilly Research Laboratories (1982) Clinical Investigation Manual LY139603. Eli Lilly and Company, Manual Identification Number: AS-6110Google Scholar
- Wong DT, Threlkeld PG, Best KL, Bymaster FP (1982) A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61–65Google Scholar